MoonLake ImmunotherapeuticsNASDAQ: MLTX

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).

MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.

MoonLake is advancing sonelokimab for conditions like psoriasis and hidradenitis suppurativa, showing positive results in Phase 2 trials. While facing competition from existing IL-17 inhibitors, MoonLake's nanobody could provide improved tissue penetration. The company is financially stable, with enough cash reserves to support operations for almost seven years, allowing for Phase 3 trials to proceed without the need for immediate funding.

MoonLake Immunotherapeutics (MLTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hidradenitis suppurativa, and psoriatic arthritis. The market for IL-17 inhibitors, like Sonelokimab, is projected to be over $50 billion by 2031, making MLTX a potentially lucrative investment.

MoonLake Immunotherapeutics shares swooned Monday after the company reported ambiguous results for its psoriatic arthritis treatment.  Patients who received MoonLake's drug, sonelokimab, did show statistically significant improvements, but patients receiving a placebo saw better-than-expected results.

MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa. Sonelokimab has shown promising results in treating psoriasis and hidradenitis suppurativa, outperforming competitors in clinical trials. The company raised $400 million and now has over $500 million in cash, providing financial stability for future development.

MoonLake is a clinical-stage biotech that focuses on inflammatory diseases. Its lead therapy, sonelokimab, is being tested against several conditions.

MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokimab's potential in treating HS, collaborating with SHL Medical for an autoinjector, and upcoming clinical trials. Given MoonLake's financial and strategic progress, the recommendation is upgraded to a "Buy" position with acknowledgement of inherent risks (e.g., Humira competition and clinical trial uncertainties).